Type 2 DiabetesSODASNCT03944616
Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes
A study testing Diet Beverage and Water in people with Type 2 Diabetes, run by University of California, Irvine at 2 sites in United States.
Trial summary
Diet beverages sweetened with artificial sweeteners occupy a unique category in the food environment as they are a source of intensely sweet taste with no calories. Diet beverages are the single largest contributor to artificial sweetener intake in the U.S. Read more about this study
- Who is it for?
- Ages 35 years and older
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- Diet Beverage and Water
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 181 participants
- Where
- 2 sitesUnited States
- Study dates
- 6 Jun 2019to 21 Mar 2024
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Type 1 diabetes or suspected type 1 diabetes (lean with polyuria, polydipsia, and weight loss with little response to metformin)
- "Secondary" diabetes due to specific causes (e.g. monogenic syndromes, pancreatic surgery, and pancreatitis)
- Diabetic Ketoacidosis hospitalization within last 6 months
- Severe/major hypoglycemia in the last 3 months-severe/major hypoglycemia is defined as a hypoglycemic event in which patient requires assistance of another person to manage the episode
- Glucocorticoid use (prednisone 2.5 mg/d or more or its equivalent)
- History of intolerance or allergy to diet beverages or AS or phenylketonuria
Show all 20Show fewer
- Any condition that is known to affect the validity of the glycemic measures (Hba1c)
- Major cardiovascular disease event or surgery within past 6 months
- Gastrointestinal disease
- Renal or liver disease
- Current treatment for cancer
- Those with major surgery planned or history of bariatric surgery
- Antibiotic treatment (> 6 days) within past 6 months
- Currently pregnant (via self-report) or planning to become pregnant during study period; <1 year postpartum and breast feeding
- Current participation in another interventional clinical trial
- Previous randomization in this study,
- Heavy alcohol consumption (on average >2 drinks/day for women and >3 drinks/day for men)
- Habitual consumer of SSB ≥ 1 serving / day (8 oz.)
- Does not drink diet beverages
- BMI < 20.0 kg/m2
Trial locations and contacts
2 sites in 1 country.
United States2 sites
University of California, Irvine
Irvine, California, 92697
University of Minnesota
Minneapolis, Minnesota, 55454
About this study
Official title: Effect of Artificially Sweetened Beverages on Diabetes Control in Adults With Type 2 Diabetes
Diet beverages sweetened with artificial sweeteners occupy a unique category in the food environment as they are a source of intensely sweet taste with no calories. Diet beverages are the single largest contributor to artificial sweetener intake in the U.S. diet, and people with diabetes are the highest consumers of diet beverages, tending to consume them as a replacement for dietary sources of sugar, especially in place of sugar-sweetened beverages. This behavior has been endorsed by dietetic and scientific organizations, and diet beverages are marketed as being synonymous with better health, suitable for weight loss, and thus advantageous for diabetes control. The underlying public health concern is that there are few data to support or refute the benefit or harm of habitual diet beverage consumption by people with diabetes; therefore randomized trials with relevant outcomes must be conducted because they would address many limitations of previous research and have major implications for dietary recommendations on diet beverage intake and primary and secondary prevention of chronic disease. To begin addressing this important scientific gap the investigators are testing the effect of diet beverage intake on diabetes control parameters in free-living adults with type 2 diabetes in a randomized, two arm parallel trial with a run-in period of 2-weeks and an active intervention period of 24-weeks. This study will recruit 200 patients with type 2 diabetes who are usual consumers of commercial diet beverages and randomize them to receive and consume either: 1) A commercial diet beverage of choice (3 servings or 24 oz. daily); or 2) Unflavored bottled water of choice (sparkling or plain) (3 servings or 24 oz. daily). The primary outcome will be a central measure of clinical diabetes control in glycated hemoglobin (HbA1c). The study will also measure the nature and magnitude of glycemic excursions via continuous glucose monitors, as well as clinical markers of cardiometabolic risk and kidney function. Lastly, investigators will measure plausible mechanisms whereby diet beverage intake may alter risk by assessing the effect of diet beverage intake on the functional composition of the gut microbiome via stool samples and comprehensive metabolomics, satiety hormones, as well as usual dietary intake, and upstream behavioral pathways which may inform dietary intake patterns.
- Conditions
- Type 2 Diabetes
- Being tested
- Diet Beverage, Water
- Keywords
- Diet beverages, diet, diabetes control, artificial sweeteners, continuous glucose monitor, gut microbiome, metabolomics
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diet BeverageBehavioural
Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
WaterBehavioural
Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
| Study group | Role | What they receive |
|---|---|---|
| Diet Beverage | Active comparator | Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners. Receives: Behavioral: Diet Beverage |
| Water | Experimental | Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages. Receives: Behavioral: Water |
What is being measured
The primary outcome is the main question the study is designed to answer.
HbA1c
Glycated hemoglobin
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Secondary outcomes (25)
Time In Range
Time in range is collected by a masked Continuous Glucose Monitor (CGM), which measures individual glucose levels every 15 minutes for two weeks via a sensor placed on the participants upper arm (underside). Time in Range is defined as the % of time each day with a glucose measure between 70-180 mg/dl. The range of CGM data for inclusion in this study will be 5 to 14 days, consistent with manufacturer's recommendations.
Measured: All 14 day periods: Run-in (2-weeks, usual-baseline), weeks 11 and 12 (14 days), weeks 23 and 24 (14 days)
Glycemic Variability
Glycemic variability is collected by a masked Continuous Glucose Monitor (CGM), which measures individual glucose levels every 15 minutes for two weeks via a sensor placed on the participants upper arm (underside). Glycemic variability is defined as the Standard Deviation (SD) of the mean glucose during the wear period. The range of CGM data for inclusion in this study will be 5 to 14 days, consistent with manufacturer's recommendations.
Measured: All 14 day periods: Run-in (2-weeks, usual-baseline), weeks 11 and 12 (14 days), weeks 23 and 24 (14 days)
Mean Glucose (mg/dl)
A measure of the mean, 24 hour glucose concentration calculated across all recorded glucose readings during the wear period
Measured: All 14 day periods: Run-in (2-weeks, usual-baseline), weeks 11 and 12 (14 days), weeks 23 and 24 (14 days)
Fasting Glucose
Standard (mg/dl) measure taken fasting (morning) during baseline, 12 weeks, 24 weeks
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Fasting Insulin (Pmol/L)
Standard lab measurement for fasting insulin assessment
Measured: Time 0 (directly after 2-week run-in), week 12, week 24
Fructosamine
Fructosamine (umol/L) represents usual glycemia over the past 2-3 weeks, and is considered a valid marker of short term clinical glycemic patterns by the American Diabetes Association
Measured: Time 0 (directly after 2-week run-in),12, 24 weeks
Weight (kg)
Weight measured on standardized scale in gown
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Total Cholesterol (mg/dL)
Total cholesterol was measured as part of a lipid panel, a standard measurement for assessing clinical CVD risk
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Kidney Function
eGFR-Cystatin-C (estimated glomerular filtration rate) = mL/min/1.73 m^2
Measured: Time 0 (directly after 2-week run-in),12, 24 weeks
Systolic Blood Pressure
Systolic blood pressure (mmHg)
Measured: Time 0 (directly after 2-week run-in),12, 24 weeks
Diastolic Blood Pressure
Standard part of blood pressure measurement (mmHG)
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Apolipoprotein-AI
Apo-AI the major protein component of high density lipoprotein (HDL)
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Apolipoprotein B
ApoB levels indicate the atherogenic particle concentration independent of the particle cholesterol content
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Fibrinogen (mg/dL)
A protein involved in forming blood clots in the body
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
C-reactive Protein
biomarker of inflammation
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Aspartate Aminotransferase (AST) (U/L)
AST (aspartate aminotransferase) is an enzyme that reflects liver function
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Aminotransferase (ALT) (U/L)
ALT (alanine transaminase) is an enzyme, a protein that reflects liver function
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Alkaline Phosphatase (ALKPhos ) (U/L)
ALP is an enzyme, a protein, that reflects liver function
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Thyroid Stimulating Hormone (TSH)
Hormone measured in the blood with energy balance related role
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Dietary Quality (Healthy Eating Index -HEI)
The Healthy Eating Index (HEI) is a measure of diet quality used to assess how well a set of foods aligns with key recommendations and dietary patterns published in the Dietary Guidelines for Americans (Dietary Guidelines). The overall HEI scores are made up of 13 components that reflect the different food groups and key recommendations in the Dietary Guidelines for Americans. The HEI is scored 0-100 (low to high), with higher scores representing greater reported intake of an overall dietary pattern aligning with USDA Dietary Guidelines. In the SODAS study, dietary intake was assessed by multiple unannounced 24-hour dietary recalls that occurred during the 2-week run-in period to assess usual habits (2 recalls over 2 weeks) and the active intervention (5 recalls over 24 weeks: 2 to 3 recalls during weeks 1-12 (period 1), and 2 to 3 recalls during weeks 13-24 (period 2). to measure any changes in diet quality. Scores during each period represent the average score of recalls.
Measured: Run-in period (2 weeks) - baseline, Week 1-12 (period 1), Week 13-24 (period 2).
The Diabetes Health Profile (DHP-18)
The Diabetes Health Profile (DHP-18) is used to assess health related quality of life in diabetes across three domains (psychological distress, barriers to activity and disinhibited eating). Each item is scored on a 4-point scale, and the subscale scores are then rescaled to a 0-100 range, with higher scores indicating poorer well-being.
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Food Craving Inventory (FCI)
The FCI is a valid and reliable self-report measure of specific food cravings. The inventory consists of 4 factors or subscales measuring cravings for high fats (8 items), carbohydrates/starches (8 items), sweets (8 items), and fast food fats (4 items), and a total score is calculated by summing the subscales. Participants rate each food on a 5-point Likert scale ranging from 0 (never) to 4 (always/almost every day). We calculated the total score by summing the individual item responses in each subscale. Higher scores indicate more frequent cravings of the 28 items.
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
The Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a one-month time interval. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties
Measured: Time 0 (directly after 2-week run-in), 12, 24 weeks
Medication Effect Score (MES)
The medication effect score (MES) is a measure of overall diabetes regimen intensity, and is based on the dosages of medications used and their potencies. The MES is calculated for each diabetes medication in a regimen using the following equation: (actual drug dose/maximum drug dose) × drug-specific adjustment factor. The adjustment factor equates to the expected decrease in HbA1c achieved by the drug as monotherapy. The MES presumes a linear relationship between medication dosage and HbA1c, and the sum of MES values attributed to individual medications represents the maximum A1c reduction that may be expected by the regimen. It is a continuous variable with range 0 (no medications), and the maximum achievable MES is patient specific and dependent on the total number of and dose of medications reported.
Measured: Time 0 (directly after 2-week run-in), 6, 12, 18, 24 weeks
Therapeutic Intensity Score (TIS)
The therapeutic intensity score (TIS) is a summary measure that accounts for the number of medications and the relative doses a patient received to lower blood pressure. It is a continuous variable with range 0 (no medications), and the maximum achievable TIS is patient specific and dependent on the total number of antihypertensive medications reported.
Measured: Time 0 (directly after 2-week run-in), 6, 12, 18, 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2019
- Study start6 Jun 2019
- Primary completion21 Mar 2024
- Study completion21 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- More trials run by University of California, IrvineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is testing the effect of commercial diet beverage intake on diabetes control parameters in free-living adults with type 2 diabetes in a randomized, two arm parallel trial with a run-in period of 2-weeks and an active intervention period of 24-weeks. We will recruit 200 patients with type 2 diabetes who are usual consumers of commercial diet beverages and randomize them to receive and consume either: 1) A commercial diet beverage of choice (3 servings or 24 oz. daily); or 2) Unflavored bottled water of choice (sparkling or plain) (3 servings or 24 oz. daily).
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 181 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Irvine
- Sponsor type
- University, hospital or other
- Collaborators
- University of Minnesota, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Responsible party
- Principal investigator, Andrew Odegaard, University of California, Irvine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03944616
- Sponsor's protocol ID
- 20184756
- Other IDs
- 1R01DK117028-01A1
- Acronym
- SODAS
- Status last verified
- Sep 2025
- First submitted
- 19 Nov 2018
- Last updated
- 11 Sep 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: It is not yet known if there will be a plan to make IPD available.
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Artificially Sweetened Beverages on Diabetes Control in Adults With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT03944616
- Acronym / sponsor ID
- SODAS / 20184756
- Conditions
- Type 2 Diabetes
- Keywords
- Diet beverages, diet, diabetes control, artificial sweeteners, continuous glucose monitor, gut microbiome, metabolomics
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 181 participants (actual)
- Lead sponsor
- University of California, IrvineUniversity, hospital or other
- Collaborators
- University of Minnesota, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- 6 Jun 2019 (actual)
- Primary completion
- 21 Mar 2024 (actual)
- Study completion
- 21 Mar 2024 (actual)
- First posted
- 9 May 2019 (actual)
- Results
- Posted 11 Sep 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Diet beverages sweetened with artificial sweeteners occupy a unique category in the food environment as they are a source of intensely sweet taste with no calories. Diet beverages are the single largest contributor to artificial sweetener intake in the U.S. diet, and people with diabetes are the highest consumers of diet beverages, tending to consume them as a replacement for dietary sources of sugar, especially in place of sugar-sweetened beverages. This behavior has been endorsed by dietetic and scientific organizations, and diet beverages are marketed as being synonymous with better health, suitable for weight loss, and thus advantageous for diabetes control. The underlying public health concern is that there are few data to support or refute the benefit or harm of habitual diet beverage consumption by people with diabetes; therefore randomized trials with relevant outcomes must be conducted because they would address many limitations of previous research and have major implications for dietary recommendations on diet beverage intake and primary and secondary prevention of chronic disease. To begin addressing this important scientific gap the investigators are testing the effect of diet beverage intake on diabetes control parameters in free-living adults with type 2 diabetes in a randomized, two arm parallel trial with a run-in period of 2-weeks and an active intervention period of 24-weeks. This study will recruit 200 patients with type 2 diabetes who are usual consumers of commercial diet beverages and randomize them to receive and consume either: 1) A commercial diet beverage of choice (3 servings or 24 oz. daily); or 2) Unflavored bottled water of choice (sparkling or plain) (3 servings or 24 oz. daily). The primary outcome will be a central measure of clinical diabetes control in glycated hemoglobin (HbA1c). The study will also measure the nature and magnitude of glycemic excursions via continuous glucose monitors, as well as clinical markers of cardiometabolic risk and kidney function. Lastly, investigators will measure plausible mechanisms whereby diet beverage intake may alter risk by assessing the effect of diet beverage intake on the functional composition of the gut microbiome via stool samples and comprehensive metabolomics, satiety hormones, as well as usual dietary intake, and upstream behavioral pathways which may inform dietary intake patterns.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- This study is testing the effect of commercial diet beverage intake on diabetes control parameters in free-living adults with type 2 diabetes in a randomized, two arm parallel trial with a run-in period of 2-weeks and an active intervention period of 24-weeks. We will recruit 200 patients with type 2 diabetes who are usual consumers of commercial diet beverages and randomize them to receive and consume either: 1) A commercial diet beverage of choice (3 servings or 24 oz. daily); or 2) Unflavored bottled water of choice (sparkling or plain) (3 servings or 24 oz. daily).
| Arm | Type | Receives |
|---|---|---|
| Diet Beverage | Active comparator | Behavioral: Diet BeverageParticipants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners. |
| Water | Experimental | Behavioral: WaterParticipants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages. |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (20 listed)
- Type 1 diabetes or suspected type 1 diabetes (lean with polyuria, polydipsia, and weight loss with little response to metformin)
- "Secondary" diabetes due to specific causes (e.g. monogenic syndromes, pancreatic surgery, and pancreatitis)
- Diabetic Ketoacidosis hospitalization within last 6 months
- Severe/major hypoglycemia in the last 3 months-severe/major hypoglycemia is defined as a hypoglycemic event in which patient requires assistance of another person to manage the episode
- Glucocorticoid use (prednisone 2.5 mg/d or more or its equivalent)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diet BeverageParticipants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners. | Behavioural | Diet Beverage |
| WaterParticipants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages. | Behavioural | Water |
Primary outcome
HbA1c
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Glycated hemoglobin
25 secondary outcomes
Time In Range
Time frame: All 14 day periods: Run-in (2-weeks, usual-baseline), weeks 11 and 12 (14 days), weeks 23 and 24 (14 days)
Glycemic Variability
Time frame: All 14 day periods: Run-in (2-weeks, usual-baseline), weeks 11 and 12 (14 days), weeks 23 and 24 (14 days)
Mean Glucose (mg/dl)
Time frame: All 14 day periods: Run-in (2-weeks, usual-baseline), weeks 11 and 12 (14 days), weeks 23 and 24 (14 days)
Fasting Glucose
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Fasting Insulin (Pmol/L)
Time frame: Time 0 (directly after 2-week run-in), week 12, week 24
Fructosamine
Time frame: Time 0 (directly after 2-week run-in),12, 24 weeks
Weight (kg)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Total Cholesterol (mg/dL)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Kidney Function
Time frame: Time 0 (directly after 2-week run-in),12, 24 weeks
Systolic Blood Pressure
Time frame: Time 0 (directly after 2-week run-in),12, 24 weeks
Diastolic Blood Pressure
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Apolipoprotein-AI
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Apolipoprotein B
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Fibrinogen (mg/dL)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
C-reactive Protein
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Aspartate Aminotransferase (AST) (U/L)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Aminotransferase (ALT) (U/L)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Alkaline Phosphatase (ALKPhos ) (U/L)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Thyroid Stimulating Hormone (TSH)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Dietary Quality (Healthy Eating Index -HEI)
Time frame: Run-in period (2 weeks) - baseline, Week 1-12 (period 1), Week 13-24 (period 2).
The Diabetes Health Profile (DHP-18)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Food Craving Inventory (FCI)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
The Pittsburgh Sleep Quality Index (PSQI)
Time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks
Medication Effect Score (MES)
Time frame: Time 0 (directly after 2-week run-in), 6, 12, 18, 24 weeks
Therapeutic Intensity Score (TIS)
Time frame: Time 0 (directly after 2-week run-in), 6, 12, 18, 24 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No. It is not yet known if there will be a plan to make IPD available.
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Diet Beverage and Water in people with Type 2 Diabetes, run by University of California, Irvine at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 11 Sep 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HbA1c (time frame: Time 0 (directly after 2-week run-in), 12, 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.